Sökresultat - Jean van Wyk

Förfina resultatet
  1. 1
    Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

    Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppresse... av Jean-Guy Baril, Jonathan B. Angel, M. John Gill, Joseph Gathe, Pedro Cahn, Jean van Wyk, Sharon Walmsley

    Publicerad 2016
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  2. 2
    Regulation of Adrenal Ornithine Decarboxylase by Adrenocorticotropic Hormone and Cyclic AMP

    Regulation of Adrenal Ornithine Decarboxylase by Adrenocorticotropic Hormone and Cyclic AMP av R Richman, C. A. Dobbins, Sandra Voina, L E Underwood, D. Mahaffee, Hillel J. Gitelman, Jean van Wyk, Robert L. Ney

    Publicerad 1973
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection

    Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection av Marta Boffito, Laura Waters, Pedro Cahn, Roger Paredes, Justin Koteff, Jean van Wyk, Tia Vincent, James F. Demarest, Kimberly K. Adkison, Romina Quercia

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  4. 4
    Barriers to access to care reported by women living with HIV across 27 countries

    Barriers to access to care reported by women living with HIV across 27 countries av Margaret Johnson, А. В. Самарина, Xi He, José Valdez Madruga, Laurent Hocqueloux, Mona Loutfy, Marie-Josée Fournelle, Michael Norton, Jean van Wyk, Woodie Zachry, Marisol Martínez

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence

    Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world eviden... av Yogesh Punekar, Daniel Parks, Mihir Joshi, SIMARJIT KAUR, Lee Evitt, Vasiliki Chounta, M. Radford, D. Jha, Shannon Ferrante, Sophia Sharma, Jean van Wyk, Annemiek de Ruiter

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  6. 6
    Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review

    Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People Wit... av Josep M. Llibre, Pedro Cahn, Janet Lo, Tristan Barber, Cristina Mussini, Berend J. van Welzen, Beatríz Hernández, Cynthia Donovan, Michelle Kisare, Myooran Sithamparanathan, Jean van Wyk

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort

    Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort av Michael Sension, Laurence Brunet, Ricky K Hsu, Jennifer S Fusco, Quateka Cochran, Christine Uranaka, Gayathri Sridhar, Vani Vannappagari, Jean van Wyk, Lewis McCurdy, Michael Wohlfeiler, Gregory Fusco

    Publicerad 2023
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  8. 8
    Reduced HIV symptoms and improved health‐related quality of life correlate with better access to care for HIV‐1 infected women: the ELLA study

    Reduced HIV symptoms and improved health‐related quality of life correlate with better access to care for HIV‐1 infected women: the ELLA study av Robert W. Baran, Fiona Mulcahy, Ivanka Krznaric, Antonella d’Arminio Monforte, А. В. Самарина, Xi He, Isabel Cassetti, José Valdez Madruga, Woodie Zachry, Jean van Wyk, Marisol Martínez

    Publicerad 2014
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI)

    Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI) av Zbyněk Straňák, Élie Saliba, Paraskevi Kosma, Klara M. Posfay‐Barbe, Khalid Yunis, Teresa Farstad, Kristina Unnebrink, Jean van Wyk, Colleen Wegzyn, Gerard Notario, Stefanie Kalus, Fiona J. Campbell

    Publicerad 2016
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  10. 10
    Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada

    Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada av Kevin Robertson, Carmen Bayón, Jean‐Michel Molina, Patricia McNamara, Christiane Resch, José A. Muñoz-Moreno, Ranjababu Kulasegaram, Knud Schewe, Angel Burgos-Ramirez, Cristina de Álvaro, Esther Cabrero, Matthew Guion, Michael Norton, Jean van Wyk

    Publicerad 2014
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  11. 11
    Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

    Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV av Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson K Wurapa, Moti Ramgopal, Peter A. Leone, Jessica Matthews, Marybeth Dalessandro, Mark Underwood, Konstantinos Angelis, Brian Wynne, Deanna Merrill, Christopher Nguyen, Jean van Wyk, Andrew Zolopa

    Publicerad 2021
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    TROCA PARA UM REGIME COM 2 MEDICAMENTOS DOLUTEGRAVIR / LAMIVUDINA (DTG / 3TC) EM DOSE FIXA COMBINADA É NÃO INFERIOR A CONTINUAR COM UM REGIME DE 3 MEDICAMENTOS POR 48 SEMANAS EM UM ENSAIO CLÍNICO RANDOMIZADO (SALSA)

    TROCA PARA UM REGIME COM 2 MEDICAMENTOS DOLUTEGRAVIR / LAMIVUDINA (DTG / 3TC) EM DOSE FIXA COMBINADA É NÃO INFERIOR A CONTINUAR COM UM REGIME DE 3 MEDICAMENTOS POR 48 SEMANAS EM UM... av Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Libby A. Blair, Brian Wynne, J Oyee, Mark Underwood, Lloyd Curtis, Gilda Bontempo, Jean van Wyk, Jucival Fernandes

    Publicerad 2022
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  13. 13
    HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

    HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review av Rickesh Patel, Lee Evitt, Ilias Mariolis, Simona Di Giambenedetto, Antonella d’Arminio Monforte, José L. Casado, Alfonso Cabello, Laurent Hocqueloux, Clotilde Allavena, Tristan Barber, Diwakar Jha, Rahul Kumar, Rahul Kamath, Tia Vincent, Jean van Wyk, Justin Koteff

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  14. 14
    Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

    Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With... av Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Stephen Taylor, Elizabeth A. Blair, Choy Man, Brian Wynne, J Oyee, Mark Underwood, Lloyd Curtis, Gilda Bontempo, Jean van Wyk

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  15. 15
    Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

    Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2... av Jean van Wyk, Chloe Orkin, Rafael Rubio, Johannes R. Bogner, David Baker, Marie-Aude Khuong-Josses, David Parks, Konstantinos Angelis, Lesley Kahl, Jessica Matthews, Ruolan Wang, Mark Underwood, Brian Wynne, Maria‐Claudia Nascimento, Kati Vandermeulen, Martin Gartland, Kimberly Y. Smith

    Publicerad 2020
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  16. 16
    Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

    Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults... av Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, Fiona Bisshop, Joaquín Portilla, Jean Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, Peter A. Leone, Keith A. Pappa, Ruolan Wang, Jonathan Wright, Nisha George, Brian Wynne, Michael Aboud, Jean van Wyk, Kimberly Y. Smith

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  17. 17
    Pregnancy outcomes and pharmacokinetics in pregnant women living with <scp>HIV</scp> exposed to long‐acting cabotegravir and rilpivirine in clinical trials

    Pregnancy outcomes and pharmacokinetics in pregnant women living with <scp>HIV</scp> exposed to long‐acting cabotegravir and rilpivirine in clinical trials av Parul Patel, Susan L. Ford, Mark Baker, Claudia Meyer, Louise Garside, Ronald D’Amico, Rodica Van Solingen‐Ristea, Herta Crauwels, Joseph W. Polli, Ciara Seal, Itziar Yagüe Muñoz, Shanker Thiagarajah, Eileen Birmingham, William Spreen, Bryan Baugh, Jean van Wyk, Vani Vannappagari

    Publicerad 2022
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  18. 18
    Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

    Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic... av Jean van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi, Joaquín Portilla, Jean‐Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, Maria Cláudia Nascimento, Keith A. Pappa, Ruolan Wang, Jonathan Wright, Allan R. Tenorio, Brian Wynne, Michael Aboud, Martin Gartland, Kimberly Y. Smith

    Publicerad 2020
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  19. 19
    Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings

    Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegra... av Celia Jonsson‐Oldenbüttel, Jade Ghosn, Marc van der Valk, Éric Florence, Francisco Jesús Vera, Christoph Stephan, Agathe Rami, Fabrice Bonnet, Laurent Hocqueloux, Kai Hove, Mounir Ait‐Khaled, Rebecca DeMoor, Gilda Bontempo, Christine L. Latham, Cassidy A. Gutner, S Iyer, Martin Gill, Maggie Czarnogorski, Ronald D’Amico, Jean van Wyk

    Publicerad 2024
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  20. 20
    Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

    Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical T... av Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Amanda E. Clarke, Chien‐Ching Hung, Jürgen K. Rockstroh, Pierre‐Marie Girard, Jörg Sievers, Choy Man, Rimgaile Urbaityte, Daisy J. Brandon, Mark Underwood, Allan R. Tenorio, Keith A. Pappa, Brian Wynne, Martin Gartland, Michael Aboud, Jean van Wyk, Kimberly Y. Smith

    Publicerad 2019
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: